P2Y 12-receptor antagonist - Novel antagonists of the P2Y12-receptor with antithrombotic effect
Keywords: P2Y 12-receptor antagonist, antithombotic effect, platelet aggregation, neuroinflammatory and neurodegenerative diseases
The P2Y12-receptor on blood platelets is the target of known antithrombotic drugs (e.g. clopidogrel). The receptor is therefore validated for this therapeutic use. Furthermore, the P2Y12-receptor is expressed in certain parts of the brain, which opens new routes for the treatment of neuroinflammatory and neurodegenerative diseases. This invention provides novel antagonists of the P2Y12-receptor. The disclosed novel compounds show reversible and selective binding to the P2Y12-receptor. The molecules do not require bioactivation. Further the patent application discloses synthesis of the compounds with optimised product yield.
- Innovative group of compounds for a validated target
- No bioactivation for faster onset of action
- Reversible binding to the receptor
- Small molecules for inexpensive production process
We offer a patent license as well as a research collaboration with licensing option to innovative companies.
Patent applications for the invention have been filed in Europe and North America.
An invention of Uni Bonn.